New asthma drug shows promise in Real-World study

NCT ID NCT06566885

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times

Summary

This study looks at how well tezepelumab works for people aged 12 and older with severe asthma in Russia. It tracks symptom control over 52 weeks using patient questionnaires. The goal is to understand the real-world benefits of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Kaliningrad, Russia

  • Research Site

    Kemerovo, Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nal'chik, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Orenburg, Russia

  • Research Site

    Petrozavodsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Shelehov, Russia

  • Research Site

    Stavropol, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Ulan-Ude, Russia

  • Research Site

    Yekaterinburg, Russia

Conditions

Explore the condition pages connected to this study.